RhoVac AB launches an English website

26 May, 2017

News from the Company 2017-05-26

RhoVac AB (“RhoVac”) today announced that the company is launching an English version of the company’s website.

RhoVac is a biotechnology company, now in clinical development, which means increased international focus. Therefore, RhoVac is launching an English version of the company’s Swedish website. The company wishes to establish a web platform that supports not only Nordic, but also international communication and thus also the visibility of the company and the company’s activities.

To further expand its international presence, the company announces that RhoVac will participate at the ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago from June 2 to June 6, 2017.

In addition, the company announces that Anders Ljungqvist, CEO, will present RhoVac and the company’s plans for 2017/2018 at Stockholm Vasa’s lunch meeting at Scandic Klara in Stockholm on 29 May and at InvestorDagen in Aarhus, Denmark, organized by Dansk Aktionærforening on June 13, 2017

For more information, please contact:
Anders Ljungqvist – VD, RhoVac AB
Phone: +45 4083 2365
E-mail: alj@rhovac.com

About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company’s main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac’s first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Stock Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016 and has approximately 1,700 shareholders. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.